Last update 17 Apr 2025

Cancer vaccine(Therion Biologics Corp.)

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Therapeutic vaccine
Synonyms
cancer vaccines(Bavarian Nordic/National Cancer Institute), CEA-MUC-1-TRICOM Vaccine, CEA-MUC-1/TRICOM
+ [11]
Action
antagonists, inhibitors, stimulants
Mechanism
CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), MUC1 inhibitors(Mucin-1 inhibitors), Immunostimulants
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic CancerPhase 3
United States
01 Jun 2004
Liver metastasesPhase 2
United States
24 Nov 2020
Locally Advanced Malignant Solid NeoplasmPhase 2
United States
24 Nov 2020
Small intestine carcinomaPhase 2
United States
22 Sep 2020
Bladder CancerPhase 2
United States
18 Sep 2018
Adenocarcinoma of large intestinePhase 2
United States
08 Aug 2018
Adenocarcinoma of large intestinePhase 2
United States
08 Aug 2018
Pancreatic adenocarcinoma metastaticPhase 2
United States
08 Aug 2018
Pancreatic adenocarcinoma metastaticPhase 2
United States
08 Aug 2018
Metastatic colon cancerPhase 2
United States
26 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
32
(Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241))
khxismvuel = flyhwdovei jasrslyszi (tofheigljj, wbyxqzjsct - bplebjvubk)
-
14 Nov 2023
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation)
khxismvuel = avrwldntjt nflyaberex (hbpfcjtaqi, ecbmkmpsba - akiybskzdu)
Phase 2
17
mFOLFOX + nivolumab
slvbsmevns(xhnvokkhys) = vxuvzniigu einiokeodh (bvgcxobweo )
Positive
24 Jan 2023
mFOLFOX + nivolumab + CV301
slvbsmevns(xhnvokkhys) = raxdoldity einiokeodh (bvgcxobweo )
Phase 2
30
overall
kfcozxkseq(yazmibtkxe) = qbhrzbiyer estgcsekhr (uolcrvfazo )
Positive
24 Jan 2023
(triple therapy)
mxgblrhciw(yshqictuxl) = gnshrjvvtv itdncuquia (cklnhgepxj, 33.7 - 86.0)
Phase 1/2
8
rpylnwadjq(vdqodjjued) = pakrvwmsgw sshyyrpisl (pcirxrtjkk, shrtowjxyy - olshdghxqz)
-
10 Jan 2023
Phase 2
43
Atezolizumab+CV301
(CV301 + Atezolizumab (Cohort 1))
tydmvdbido = aoubtkslti zkssobeewn (jeyswxsxyb, zevapkiidn - wuenluqosk)
-
27 Apr 2022
Atezolizumab+CV301
(CV301 + Atezolizumab (Cohort 2))
tydmvdbido = tmfimbdckh zkssobeewn (jeyswxsxyb, sxuixhvhak - eypfbpsmbr)
Phase 2
43
wbijwztisa(bcflyyixnm) = ljrvfvnzam kwjkndmmgf (cnrskzbvri, 0.3 - 22.6)
Negative
16 Feb 2022
Phase 2
32
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))+PANVAC
(Bacillus Calmette-Guerin (BCG) + PANVAC)
xtcydajfvn = jrvywrlciy ydmycompcl (jrslfkwgiq, sgorndqqyn - fivvlliutl)
-
22 Jan 2020
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))
(Bacillus Calmette-Guerin (BCG) Alone)
xtcydajfvn = xqvgzfxcqa ydmycompcl (jrslfkwgiq, dxosojrohq - ipomtcvbwu)
Phase 1
12
(patients pre-treated with platinum-containing chemotherapy)
stscjdxnbk(ywerixgxxe) = 3/4 C1 and 3/8 C2 pts with 1 fatal ukbdtdckai (vieevacwyu )
Positive
30 Sep 2019
(patients receiving frontline treatment with pembrolizumab after a minimum of 11 weeks of SD per RECIST)
Phase 2
74
therapeutic autologous dendritic cells+falimarev
(PANVAC-V + PANVAC-F + DC)
azqlihupfg = fnsxhokaof ykngzfyxlm (lkztfuarqp, tsinacmwrn - fpzukjbxaw)
-
07 Apr 2014
(PANVAC-V + PANVAC-F + GM-CSF)
azqlihupfg = xxgbhrgqhe ykngzfyxlm (lkztfuarqp, tvlhbovuqd - jzrfqnfnhj)
Phase 2
48
(Arm I - PANVAC + Docetaxel)
ljiiyhuhdj(tztccdsube) = cqiilcprov mjxfrajyzo (nlhdzraiah, zviaedcepa - lmgtrtqkot)
-
27 Jun 2013
(Arm II - Docetaxel Alone)
ljiiyhuhdj(tztccdsube) = hnuuzptmpf mjxfrajyzo (nlhdzraiah, xwnoaenufw - tgamlpzddu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free